Biopharmaceuticals Radiology Oncology Personnel

 News Release - September 16, 2010

FluoroPharma Inc. Appoints Mr. Thijs Spoor as Chief Executive Officer and Director

BOSTON, Sept. 16 -- (Healthcare Sales & Marketing Network) -- FluoroPharma, an independent privately held biopharmaceutical company engaged in discovery and development of imaging radiopharmaceuticals for use in cardiology and Alzheimer's disease, announced today the appointment of Thijs Spoor as the new CEO in conjunction with his appointment to its Board of Directors. Mr. Spoor has 15 years of international experience in the medical industry across a variety of roles including Regulatory Affairs, New Product Development and as the Global Brand Head for Nuclear Cardiology at (Amersham) GE Healthcare and most recently as the CFO of Sunstone BioSciences. He also spent 4 years on Wall Street at J.P. Morgan and Credit Suisse where he covered biotechnology and medical device stocks. He trained as a nuclear pharmacist and holds a Pharmacy degree from the University of Toronto and an MBA from Columbia University.

Mr. Spoor joined the Board of Directors consisting of Dr. David Elmaleh, Chairman and Scientific founder, Dr. Peter Conti and Mr. Walter Witoshkin. "I am pleased to welcome Mr. Spoor to our Board of Directors," said Dr. Conti. "He brings substantial industry and capital markets experience which will be an asset to the team as we continue to work toward developing diagnostic agents for discrete unmet medical needs." "Our Board and our Company got stronger today," said Dr. David Elmaleh Founder, Chairman and Chief Scientific Officer of FluoroPharma. "As we turn to the rest of 2010 and beyond, we are focused on creating investor value by furthering the field of molecular imaging. Mr. Spoor will help us achieve our goals by leveraging his experience and proven track records of success. I'm excited to begin working with him on the future of our Company." Mr. Spoor had previously been an advisor to the company and joined the company effective September 3rd. "I am excited to help take FluoroPharma's unique portfolio closer to becoming an integral portion of patient care," said Spoor. "The company's products address specific unmet medical needs which have long been pursued in the field of molecular imaging."

About FluoroPharma Inc.

FluoroPharma is an independent privately held biopharmaceutical company engaged in the discovery and development of proprietary products for the PET market. FluoroPharma is advancing proprietary products for assessment of acute and chronic forms of coronary disease. These agents have been designed to rapidly target either the myocardial cells within the heart or inflamed plaques within the coronary arteries.

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the company's need for additional funds, the company's dependence on a limited number of imaging compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. Furthermore, forward-looking statements speak only as of the date they are made. FluoroPharma does not undertake any obligation to update or review any such forward-looking information, whether as a result of new information, future events or otherwise.

Source: FluoroPharma

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.